Skip to main content
SpringerLink
Log in

Risk Factor Management of Atherosclerotic Peripheral Vascular Disease

  • Chapter
  • First Online:
Handbook of Endovascular Peripheral Interventions

  • 1601 Accesses

Abstract

Individuals with atherosclerotic peripheral vascular disease (APVD) are at significantly increased risk of adverse cardiovascular events such as myocardial infarction, stroke, and death. 1, 2 Accordingly, the management of all patients with APVD should include comprehensive risk factor modification that is focused on the secondary prevention of cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Bibliography

  1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-654.

    Article  PubMed  Google Scholar 

  2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67. ® The preceding two references provide a comprehensive review of the management of patients with atherosclerotic peripheral vascular disease, including detailed review of the existing literature and inter-societal guidelines for specific management of atherosclerotic risk factors.

    Article  PubMed  Google Scholar 

  3. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. Jama. 2003;290:86–97.

    Article  PubMed  Google Scholar 

  4. Fiore MC JC, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. April 2009. ® A clinical practice guideline for smoking cessation compiled by the United States Public Health Service.

    Google Scholar 

  5. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–229.

    Article  PubMed  CAS  Google Scholar 

  6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine. 1993;329:977–986.

    Article  Google Scholar 

  7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.

    Article  PubMed  Google Scholar 

  8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853. ® The preceding three references represent landmark clinical trials examining the effect of intensive glucose lowering on macrovascular and microvascular complication in patients with diabetes.

    Article  Google Scholar 

  9. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.

    Article  PubMed  CAS  Google Scholar 

  10. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.

    Article  PubMed  CAS  Google Scholar 

  11. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  12. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772. ® Meta-analysis of existing randomized clinical trials, including the three preceding references, on the impact of glucose lowering for reduction of cardiovascular outcomes in patients with diabetes.

    Article  PubMed  CAS  Google Scholar 

  13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193–203. ® Consensus statement from the American Diabetes Association and the European Association for the study of diabetes on guidelines for the medical management of diabetes.

    Article  PubMed  CAS  Google Scholar 

  14. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) ALLHAT Collaborative Research Group. JAMA. 2000;283:1967–1975. ® The ALLHAT study was a landmark clinical trial demonstrating the benefit of anti-hypertensive medications on reducing major caridovascular events.

    Article  Google Scholar 

  15. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652.

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153.

    Article  PubMed  CAS  Google Scholar 

  17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.

    Google Scholar 

  18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. ® The preceding two references highlight two large clinical ­trials in greater than 20,000 patients establishing the role of cholesterol lowering and statin medications in particular in cardiovascular risk reduction in patients with vascular disease.

    Article  Google Scholar 

  19. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology. 2009;8:453–463. ® Meta-analysis of the impact of statin therapy on prevention of stroke.

    Article  PubMed  CAS  Google Scholar 

  20. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497. ® Summary of the recommendations from the NCEP ATP III on the management of patients with hyperlipidemia.

    Google Scholar 

  21. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585–1591.

    Article  PubMed  CAS  Google Scholar 

  22. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, D’Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Reena L. Pande & Mark A. Creager

Authors
  1. Reena L. Pande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark A. Creager
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark A. Creager .

Editor information

Editors and Affiliations

  1. Division of Vascular Surgery, University of California San Francisco, Department of Surgery, Parnassus Avenue 400, San Francisco, 94143, California, USA

    Christopher D. Owens

  2. Medical Center, Cardiology Div., University of California, San Francisco, Parnassus Ave. 505, San Francisco, 94143, California, USA

    Yerem Yeghiazarians

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pande, R.L., Creager, M.A. (2012). Risk Factor Management of Atherosclerotic Peripheral Vascular Disease. In: Owens, C., Yeghiazarians, Y. (eds) Handbook of Endovascular Peripheral Interventions. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-0839-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0839-0_10

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-0838-3

  • Online ISBN: 978-1-4614-0839-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation